<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01091649</url>
  </required_header>
  <id_info>
    <org_study_id>M10-797</org_study_id>
    <nct_id>NCT01091649</nct_id>
  </id_info>
  <brief_title>Study in Healthy Adults to Evaluate the Bioavailability of Two Test Tablet Formulations of ABT-450</brief_title>
  <official_title>An Open-label, Randomized, Crossover Study to Evaluate the Bioavailability of Two Candidate Tablet Formulations of ABT-450 With Reference to the Hard Gelatin Capsule Formulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the relative bioavailability of two test tablet
      formulations of ABT-450 as compared to the ABT-450 hard gelatin capsule formulation as a
      reference.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a two part study. Part 1 is a single dose, three period, complete crossover study in
      approximately 21 subjects. Part 2 is a single dose, two period, complete crossover study in
      approximately 20 subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of Pharmacokinetics of two ABT-450 tablet formulations plus ritonavir and the ABT-450 capsule formulation plus ritonavir. Each dosed at low ABT-450/ritonavir</measure>
    <time_frame>72 hrs post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of Pharmacokinetics of the selected ABT-450 tablet formulations plus ritonavir and the ABT-450 capsule formulation plus ritonavir. Each dosed at high ABT-450/ritonavir</measure>
    <time_frame>72 hrs post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To tabulate treatment emergent adverse events of two ABT-450 tablet formulations plus ritonavir and the ABT-450 capsule formulation plus ritonavir</measure>
    <time_frame>Through 30 days post last dose.</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Low dose ABT-450 capsule and ritonavir capsules (reference).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Low dose ABT-450 SDD Tablet Form 1 and ritonavir capsules (test 1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Low dose ABT-450 SDD Tablet Form 2 and ritonavir capsules (test 2).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>High dose ABT-450 capsule and ritonavir capsules (reference).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>High dose ABT-450 SDD Tablet Form 1 or 2 and ritonavir capsule (test)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-450</intervention_name>
    <description>Low dose ABT-450 / ritonavir see Arm Description for more information</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ritonavir</intervention_name>
    <description>ritonavir see Arm Description for more information</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>D</arm_group_label>
    <arm_group_label>E</arm_group_label>
    <other_name>ABT-538, ritonavir, Norvir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-450</intervention_name>
    <description>High dose ABT-450 / ritonavir See Arm Description for more information</description>
    <arm_group_label>D</arm_group_label>
    <arm_group_label>E</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Overall healthy subjects

          -  Non-childbearing potential females included

        Exclusion Criteria

          -  Positive test for HAV IgM, HBsAg, anti-HCV Ab or anti-HIV Ab

          -  Clinically significant cardiovascular, respiratory (except mild asthma), renal,
             gastrointestinal, hematologic, neurologic, thyroid, or any uncontrolled medical
             illness or psychiatric disorder

          -  Use of tobacco or nicotine-containing products with the 6-month period prior to study
             drug administration

          -  Abnormal screening laboratory results that are considered clinically significant by
             the investigator

          -  Pregnant or breastfeeding female; requirement for any OTC and/or prescription
             medication, vitamins and/or herbal supplements on a regular basis

          -  Previous exposure to ABT-450
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adebayo Lawal, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 27781</name>
      <address>
        <city>Waukegan</city>
        <state>Illinois</state>
        <zip>60085</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2010</study_first_submitted>
  <study_first_submitted_qc>March 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2010</study_first_posted>
  <last_update_submitted>December 17, 2010</last_update_submitted>
  <last_update_submitted_qc>December 17, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 21, 2010</last_update_posted>
  <responsible_party>
    <name_title>Adebayo Lawal, Global Project Director</name_title>
    <organization>Abbott</organization>
  </responsible_party>
  <keyword>Pharmacokinetics, Safety</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

